Intellia Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA
Portfolio Pulse from
Levi & Korsinsky law firm has filed a class action securities lawsuit against Intellia Therapeutics, alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced halting the NTLA-3001 research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.
April 03, 2025 | 6:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intellia Therapeutics is facing a class action lawsuit alleging securities fraud, which could potentially impact investor confidence and stock performance.
The lawsuit and strategic restructuring suggest potential financial and reputational challenges for Intellia, likely causing short-term negative market sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100